
A randomised controlled trial of the efficacy and safety of allopurinol dose escalation t... $1/5 \sim - \Im$

This site uses cookies. More info



http://ard.bmj.com/content/early/2017/03/17/annrheumdis-2016-210872

Two fifths of all

older people in the UK say television is

their main form of

company.

SOTHEBY MEWS 115

Want to help them get out of the house?

Trial registration number: ANZCTR12611000845932; Results.

http://dx.doi.org/10.1136/annrheumdis-2016-210872

Statistics from Altmetric.com



Picked up by **2** news outlets Tweeted by **7**

6 readers on Mendeley

See more details

View Full Text

Footnotes

Handling editor Tore K Kvien

Contributors: LKS and ND: literature search, study design, data collection, data analysis, data interpretation and manuscript preparation. PTC and JD: study design, data collection, data analysis, data interpretation and manuscript preparation. MLB and CF: study design, data analysis, data interpretation and manuscript preparation. AH and PT: data collection, data analysis, data interpretation and manuscript preparation.

Funding: This study was funded by the Health Research Council of New Zealand (11/203).

Competing interests: LKS reports grants from Health Research Council of New Zealand, during the conduct of the study; grants from Ardea Biosciences, grants from Health Research Council of New Zealand, outside the submitted work; AH reports grants from Health Research Council of New Zealand, during the conduct of the study; ND reports grants from Health Research Council of New Zealand, during the conduct of the study; grants from Health Research Council of New Zealand, during the conduct of the study; grants from Health Research Council of New Zealand, during the conduct of the study; grants from Health Research Council of New Zealand, during the conduct of the study; grants from Health Research Council of New Zealand, grants and personal fees from AstraZeneca, grants and personal fees from Ardea Biosciences, personal fees from Takeda, personal fees from Teijin, personal fees from Menarini, grants from Fonterra, personal fees from Pfizer, personal fees from Crealta, personal fees from Cymabay, outside the submitted work.

Patient consent: Obtained.

Ethics approval: MultiRegional Ethics Committee of New Zealand.

Provenance and peer review: Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center's RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Request permissions


Copyright information: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Read the full text or download the PDF:

Buy this article

Subscribe

Log in



We recommend

Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study) Thomas Bardin et al., Ann Rheum Dis, 2016

A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. M K Reinders et al., Ann Rheum Dis, 2008

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol Chris Storgard et al., Ann Rheum Dis, 2016

Lesinurad combination therapy with allopurinol in gout: do CLEAR studies make the treatment of gout clearer?

Jasvinder A Singh, Ann Rheum Dis, 2016

Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. M K Reinders et al., Ann Rheum Dis, 2008



CONTENT

Latest content

Current issue

Archive

Browse by topic

Most read articles

JOURNAL

About Editorial board Thank you to our reviewers Sign up for email alerts Subscribe EULAR textbooks

AUTHORS

A randomised controlled trial of the efficacy and safety of allopurinol dose escalation t... $5/5 \sim - \Im$

Instructions for authors Submit an article Open Access at BMJ

HELP

Contact us

Reprints

Permissions

Advertising

Feedback form



BMJ

Website Terms & Conditions Privacy & Cookies Contact BMJ

Online: ISSN 1468-2060 Print: ISSN 0003-4967 Copyright © 2017 BMJ Publishing Group Ltd & European League Against Rheumatism. All rights reserved. 京ICP备15042040号-3